The presentation of positive clinical trial data at a major oncology conference like ASCO is likely to boost investor confidence in TriSalus Life Sciences. The PEDD™ technology's potential to improve drug delivery in challenging tumor environments could be seen as a significant advancement, potentially driving the stock price up in the short term.